NeuroSense Therapeutics Warrant
NRSNW
4 hedge funds and large institutions have $25K invested in NeuroSense Therapeutics Warrant in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
1.22% less ownership
Funds ownership: 2% → 0.78% (-1.2%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
75% less capital invested
Capital invested by funds: $98.9K → $25K (-$73.9K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$139 |
| 2 |
CS
Clear Street
New York
|
+$23 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$36.4K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$4.29K |
| 3 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$2.16K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
1
Clear Street
New York
| $12.2K | +$23 | +100 | +0.2% |
|
|
WAM
2
Warberg Asset Management
Winnetka,
Illinois
| $6.59K | -$2.16K | -9,400 | -23% |
|
|
3
Citadel Advisors
Miami,
Florida
| $6.07K | -$4.29K | -18,674 | -39% |
|
|
4
UBS Group
Zurich,
Switzerland
| $125 | +$139 | +605 | New |
|
|
5
Hudson Bay Capital Management
Stamford,
Connecticut
| – | -$36.4K | -86,753 | Closed |
|
NRSNW Hedge Fund Activity: Q2 2024 in Review
4 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics Warrant (NRSNW) for Q2 2024, worth a combined $25K — down 75% from $98.9K a quarter earlier.
Fund positioning in NRSNW was balanced in Q2 2024: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $139. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $36.4K sold.
- 4 institutional investors held NeuroSense Therapeutics Warrant (NRSNW) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $25K of NeuroSense Therapeutics Warrant stock for Q2 2024, down 75% quarter-over-quarter.
- 1 fund opened new NeuroSense Therapeutics Warrant positions in Q2 2024 and 1 closed out, a net change of 0 holders.
- The largest NeuroSense Therapeutics Warrant buyer in Q2 2024 was UBS Group, an estimated $139 added.
- The largest NeuroSense Therapeutics Warrant seller in Q2 2024 was Hudson Bay Capital Management, an estimated $36.4K sold.
Based on aggregated 13F filings for Q2 2024.